Mirum Pharmaceuticals.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Earlier this month
-
Mirum Pharmaceuticals received positive analyst rating updates, including buy ratings and raised price targets, from multiple firms including CLSA and Morgan Stanley.Some support2 reports
-
Fate Therapeutics and Mirum Pharmaceuticals are now listed on the Nasdaq stock exchange.Some support1 report
-
Trump's pledge to unleash oil and gas benefits stocks, specifically impacting Mirum Pharmaceuticals.Some support4 reports
One to three months ago
Gone quiet
No new reports in 90+ days-
Garcia received a BA from Stanford University and an MBA from UCLA Anderson. The individual also previously held senior finance roles at Amgen. Separately, Bluejay Therapeutics was acquired by Mirum.Some support1 report
-
FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.Some support2 reports
-
Mirum Pharmaceuticals developed treatments for rare diseases in July 2025.Some support1 report
-
Mirum Pharmaceuticals operates within the US market.Some support1 report
-
FDA approved several medications developed by Mirum Pharmaceuticals on July 31, 2025.Some support1 report
-
Mirum Pharmaceuticals reported notable outperformance on August 7, 2025, and Chris Peetz was confirmed as the chief executive officer.Some support1 report
-
Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.Some support1 report
-
Mirum Pharmaceuticals participated in a conference hosted by Morgan Stanley on August 28, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Mirum Pharmaceuticals this week
News at the entities that move Mirum Pharmaceuticals most-
FDA StructuralBMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Moves Mirum Pharmaceuticals
-
SEC StructuralIntuit filed a Form 4 with the SEC regarding insider share sales on August 30, 2026.Moves Mirum Pharmaceuticals
-
CLSA Mentioned togetherCLSA retained an 'outperform' rating on M&M, and UBS acquired a stake in an Indian company.Moves Mirum Pharmaceuticals
-
MarketBeat Mentioned togetherMarketBeat identifies Celsius Network as a stock to watch, noting that the company sells products across multiple continents, including Europe.Moves Mirum Pharmaceuticals
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada adjusted its holdings in the Simplify Hedged Equity ETF on October 22, 2026.Moves Mirum Pharmaceuticals
-
Morgan Stanley OperationalMorgan Stanley increased its price target for SLM Corporation on September 2, 2026.Moves Mirum Pharmaceuticals
Connections
The 17 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA serves as the formal regulatory body whose approvals and reviews are essential for Mirum Pharmaceuticals to bring its treatments to market.
-
SEC Structural
Mirum Pharmaceuticals is formally regulated by the SEC and must file required disclosures.
-
Morgan Stanley Operational
Morgan Stanley provides market coverage, including price targets and rating upgrades, for Mirum Pharmaceuticals.
-
Europe Shared context
Mirum Pharmaceuticals operates and targets adult patients within the European market following product approval.
-
Erin Murphy Operational
Erin Murphy serves as the designated media contact for Mirum Pharmaceuticals.
-
Incyte Operational
The two companies are actively collaborating on the PROGRESS study.
-
MarketBeat Mentioned together
MarketBeat provides consensus ratings and market coverage for Mirum Pharmaceuticals.
-
CLSA Mentioned together
CLSA provides financial research, price targets, and rating updates for Mirum Pharmaceuticals.
Show all 17 connections
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis, including price targets and rating reports, for Mirum Pharmaceuticals.
-
Instagram Operational
Mirum Pharmaceuticals utilizes Instagram as a platform for corporate communication.
-
Natera Operational
Mirum Pharmaceuticals and Natera are actively competing within the biopharmaceutical sector.
-
Amsterdam Shared context
Mirum Pharmaceuticals conducts scientific presentations at events held in Amsterdam.
-
Raymond James Financial Mentioned together
Raymond James Financial provides sell-side analyst coverage for Mirum Pharmaceuticals, maintaining a strong buy rating.
-
TD Cowen Mentioned together
TD Cowen provides financial analysis, including buy ratings and price targets, for Mirum Pharmaceuticals.
-
Citigroup Operational
Citigroup provided an outperform rating on Mirum Pharmaceuticals.
-
Nasdaq Shared context
Mirum Pharmaceuticals is listed and trades on the Nasdaq stock exchange.
-
Garcia Mentioned together
No evidence linking Mirum Pharmaceuticals and Garcia was found in the provided timeline.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
1 eventJune 2026
11 events- Mirum Pharmaceuticals received positive analyst rating updates, including buy ratings and raised price targets, from multiple firms including CLSA and Morgan Stanley.
- Trump's pledge to unleash oil and gas benefits stocks, specifically impacting Mirum Pharmaceuticals.
- Mirum Pharmaceuticals trades on the Nasdaq exchange.
- Garcia received a BA from Stanford University and an MBA from UCLA Anderson. The individual also previously held senior finance roles at Amgen. Separately, Bluejay Therapeutics was acquired by Mirum.
- FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.
- Mirum Pharmaceuticals developed treatments for rare diseases in July 2025.
- Mirum Pharmaceuticals operates within the US market.
- FDA approved several medications developed by Mirum Pharmaceuticals on July 31, 2025.
- Mirum Pharmaceuticals reported notable outperformance on August 7, 2025, and Chris Peetz was confirmed as the chief executive officer.
- Albireo, Mirum Pharmaceuticals, and Ipsen are developing IBAT inhibitor therapies targeting conditions like MASH.
- Mirum Pharmaceuticals participated in a conference hosted by Morgan Stanley on August 28, 2025.